Introduction
Influenza is an important infection to consider in SCT recipients. [1] [2] [3] [4] [5] The mortality was reported to be around 15% in untreated patients, 3, 4 although more recent data reporting outcome after neuramidase treatment suggest lower risk for fatal outcome. 5, 6 The mortality is highest in patients developing pneumonia. 5 Fatal influenza infections can occur several years after an allogeneic SCT, in particular, in patients with chronic GVHD. 4 The primary mode for prevention of influenza is vaccination and this paper aims to review available data regarding safety and efficacy of influenza vaccination.
Immune response to influenza virus
Influenza causes an acute infection in the host and initiates several parts of the immune system. The initial innate immune response, including release of type I INFs and influx of granulocytes and natural killer cells, limits viral replication and is essential for the activation of the adaptive immune response. Natural killer cells also contribute to the immunity against influenza: an activating natural killer cell receptor, NKp46, has been stated to recognize and kill influenza virus-infected cells. 7 Both CD4 and CD8 T cells are vigorous in mediating control of an influenza infection. Clearance of the primary infection depends on CD8 cells. These cells recognize epitopes from the hemagglutinin (HA) or internal proteins M, NP or PB2 presented on MHC class I molecules. 8 Depending on their antigen specificity, cytotoxic T lymphocytes may be subtype-specific or, in case they recognize internal antigens, broadly crossreactive with different influenza A strains. Following recovery from influenza, antigen-specific T cells maintain long-lasting immunological memory that responds quickly to antigen restimulation. Memory is maintained by antigen-specific T cells that persist at increased frequencies, have reduced requirements for co-stimulatory signals in comparison to naive T cells and respond quickly to antigenic restimulation. 9 The B cells produce antibodies to the influenza glycoproteins that is, HA and neuramidase, as well as to the M and NP proteins. HA-specific antibodies appear within 2 weeks of virus inoculation. A primary infection is accompanied by a transient IgM response followed by persistent elevated IgA and IgG levels. Mucosal IgA neutralizes and clears viral infection in upper airways, whereas IgG is responsible for the protection of the lower respiratory tract. Either mucosal or systemic antibodies can be protective if present in sufficient concentrations, but optimal protection occurs when both types are present. Serum inhibiting titers of 1:40 or greater are supposed to protect against infection. Higher antibody levels are required for protection in individuals with impaired immunity. 10 In contrast to antibodies directed to HA, antibodies directed to neuramidase do not neutralize virus but reduce the release of virus from infected cells.
A specific problem for the immune system to handle both regarding natural and vaccine-induced immunity is the antigenic shifts and drifts that occur with influenza infections. Major antigenic shifts can result in pandemics such as the Spanish flu during the First World War and the Asian flu in the late 1950s. The less dramatic antigenic drifts are caused by accumulations of point mutations in the RNA segment coding for the HA resulting in aminoacid substitutions in the antigenic sites of the protein. These changes result in a constant need for overseeing the content of the yearly influenza vaccine, and sometimes the vaccine might not cover the currently circulating influenza strain. Whether antigenic drift impacts more on the immunocompromised patients than in healthy individuals has not been studied but it could be envisaged that patients with poorer antibody-producing capacity and smaller numbers of B cells and plasma cells might be less able to create an immune response with antibodies with lower affinity but still able to modify the risk for influenza.
Existing vaccines
Two main types of influenza vaccine exist: inactivated and live, cold-adapted vaccine for intranasal administration. The inactivated vaccines can be produced either as whole virus vaccine, split vaccines or subunit vaccines. There are no data in hematopoietic SCT (HSCT) patients suggesting that one type of inactivated vaccine is more efficient in inducing an immune response. Safety and efficacy of the intranasal live vaccine has not been evaluated in HSCT recipients or other severely immunocompromised patient groups. One study in HIV-infected patients with CD4 counts above 200 cells/mm 3 did, however, not show any increased risk for side effects during a 1 month follow-up period.
11 Similarly, no difference in adverse effects was seen in HIV-infected children on highly active antiretroviral treatment (HAART) therapy. 12 Currently it should, however, not be used until studies in HSCT recipients have been performed. Other vaccine types based on more conserved influenza proteins are in development but are currently not available.
Vaccination of candidates before HSCT
As influenza infection occurring early after HSCT might result in severe disease, it would be logical to immunize candidates before HSCT. However, most studies show that adult patients with hematological malignancies respond poorly to vaccination. In a study including patients with multiple myeloma, the response rate to one dose of vaccine was only 19%. 13 Similar results have been seen in patients with lymphoma.
14 One possible way to improve the results is to give repeated doses of vaccine. Adults with lymphoma receiving a two-dose schedule showed responses of approximately 30% after one dose and approximately 45% after two doses of vaccine. 15 However, two studies failed to show an improvement by addition of a second dose to patients with various hematological malignancies 16 or chronic lymphocytic leukemia. 17 Preliminary data suggest that vaccination results of patients having received rituximab or alemtuzumab for lymphoma are very poor. 16 These results indicate that vaccination of patients before HSCT is unlikely to confer protective immunity. In addition, as these data indicate low number of influenzaspecific memory cells, the likelihood that whatever immunity that does exist will be lost is very high.
Influenza vaccination after allogeneic hematopoietic SCT
It is important to recognize that there are limitations to the existing data. Most studies have been performed in patients receiving myeloablative conditioning regimens with either HLA-matched family donors or well-matched unrelated donors. 18, 19 Only limited data exist in patients having received reduced-intensity conditioning regimens 20 and there is almost no data in patients receiving cord blood or haplo-identical grafts. Existing data are also limited for children. In addition, with one exception, studies report the effect of the vaccine in inducing antibody responses and not protection against infection or indeed severe disease.
Timing of vaccination after HSCT
Severe infections frequently occur early after SCT when immunizations are ineffective. Whether a pretransplant immunization of the marrow donor would be beneficial has not been studied. It has been shown that the time after SCT is important for vaccine efficacy, with patients vaccinated later after SCT having better responses. Engelhard et al. 18 studied the antibody response to two doses of influenza virus vaccine in 35 allogeneic BMT recipients (adults and children), who received a T-depleted transplant and vaccinated between 2 and 82 months (median 14.5 months) after HSCT. They found a statistically significant association between development of protective antibody levels (HAA-inhibition titer X1:40) and the time interval between BMT and initial vaccination (Pp0.001). No patient vaccinated before 6 months after BMT responded. The second vaccine dose had only a marginal effect. In a study by Pauksen et al., 19 the response rates defined as fourfold antibody titer increases in allogeneic SCT patients vaccinated 4-12 months after HSCT were 11 of 35 (31%) for H1N1, 3 of 35 (9%) for H3N2 and 7 of 35 (20%) for influenza B. The corresponding numbers for patients vaccinated later than 12 months after HSCT were 2 of 15 (13%), 6 of 15 (40%) and 5 of 15 (33%) for H1NI, H3N2 and influenza B, respectively. In a recent study, Avetisyan et al. 21 found that 4 of 14 patients vaccinated between 3 and 24 months after HSCT had protective antibody levels. They also studied the in vitro B-cell responses by ELISPOT and found a significantly stronger increase after vaccination in healthy controls compared to HSCT recipients and stronger responses in HSCT recipients vaccinated more than 6 months after HSCT. Gandhi et al. 22 vaccinated eight adult HSCT recipients at a median of 16 months after HSCT and none responded with protective antibody levels to all three subtypes included in the vaccine. In a small study, Haining et al. 23 vaccinated four children 4-22 months after HSCT and none had a serological response.
However, despite suboptimal serological responses, there might still be clinical effectiveness of vaccination. Machado et al. 20 found that influenza vaccination performed at least 6 months after SCT had an efficacy in preventing influenza of 80%. In this study, patients who complied with the recommendation to be vaccinated had a lower risk (2 of 19) to develop virological confirmed influenza compared to patients who did not get vaccinated (12 of 24) . In a multivariate analysis of risk factors, they found that influenza vaccination reduced the risk for influenza but that time after HSCT (6 months or later) had no impact. No data were presented regarding the antibody response to vaccination.
Influence of GVHD
The results of the different studies in the presence of GVHD are mixed. Engelhard et al. 18 noted a reduction in the response rates to H1N1 but not to the other components of the vaccine. Pauksen et al. 19 were unable to find any influence of GVHD, whereas Machado et al. 20 noted in a multivariate analysis a protective effect of ongoing corticosteroid therapy.
Influence of conditioning regimens
Pauksen et al. 19 found no influence of TBI in the conditioning regimen, whereas Machado et al. 20 found that more intensive conditioning regimens including TBI of the combination of BU and melphalan increased the risk for influenza.
Other factors
Pauksen et al. 19 investigated the addition of GM-CSF to influenza vaccine and found a minor improvement in the response to influenza B vaccine.
T-cell immune responses
Three studies have analyzed the T-cell response to influenza vaccine. Haining et al. 23 studied the in vitro responses to H3N2 viral lysate in four children vaccinated 4-22 months after allogeneic HSCT. They found a CD4 þ response in all four children but no increase in serum antibody levels. Avetisyan et al. 21 used peptides from the HA and M1 protein as stimulators analyzing the T-cell response in 18 adult patients 3-24 months after allogeneic HSCT. They found a significant increase in the number of g-IFNproducing T-cells both in patients vaccinated between 3-6 months after HSCT and in those vaccinated later, although the response in the late group was stronger. They also found a significant increase in the number of influenzaspecific T-cells analyzed by the pentamer technique.
Influenza vaccine in autologous SCT recipients
The response to vaccination is likely to be suboptimal early after transplantation, also in autologous HSCT recipients. Engelhard et al. 18 showed that no patient responded if the immunization was performed earlier than 6 months after autologous BMT. Pauksen et al. 19 documented response rates in autologous SCT patients vaccinated 4-12 months after HSCT of 14 of 47 (30%) for H1N1, 15 of 47 (32%) for H3N2 and 18 of 47 (38%) for influenza B. The corresponding numbers for patients vaccinated later than 12 months after HSCT were 7 of 14 (50%), 7 of 14 (50%) and 10 of 14 (71%) for H1NI, H3N2 and influenza B, respectively. Gandhi et al. 22 found responses to one or two influenza subtypes in approximately 20% of both auto BMT and auto PBSCT recipients vaccinated around 1 year after SCT, whereas the response to all three subtypes were around 10% in both groups.
No specific data exist regarding vaccine efficacy in patients having received rituximab in close proximity to the transplantation either during pretransplant chemotherapy, as a part of the conditioning regimen, or after the transplantation. However, it has been shown in nontransplant patients that the response within 6 months of therapy with MoAb is very poor 16 and it is therefore likely that the same will be the case after autologous SCT.
Side effects
The reported side effects have been mild and no different from what could be expected in healthy controls. No study has reported an increased risk for GVHD but it has to be recognized that all the studies have been relatively small. One case report has been published reporting a possible association between influenza vaccination and development of thrombocytopenia. 24 
Recommendations for influenza vaccination of HSCT recipients
Despite the limited data existing, life-long seasonal influenza vaccination with inactivated influenza vaccine is recommended for all HSCT recipients. [25] [26] [27] Existing data support a recommendation to vaccinate patients between 6 months and 2-3 years after HSCT, as the study by Machado et al. 20 strongly suggests a risk reduction in influenza by vaccination. However, the existing data supporting the recommendation to vaccinate earlier or later after HSCT are less robust.
One problem is how early after HSCT vaccination is meaningful. The fact that a fourfold rise in antibody titers is rarely found does not necessarily mean that vaccination is without value. It has been shown in a human challenge model that it is difficult to infect healthy adults when serum HI titers are above 1:8, and in patients with lower levels, nasal IgA and cytotoxic T lymphocyte might also play a role. 28 Interestingly, the data by Avetisyan et al. 21 suggest that influenza-specific T-cell responses can be elicited in patients vaccinated 3-6 months after HSCT and these might be able to modify the course of the infection, and it has been shown in the elderly that the risk for influenza disease was comparable in individuals demonstrating a cellmediated response alone, an antibody response alone or both types of responses. 29 
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Another problem with interpreting currently available data is that most studies have been performed in patients, who have received myeloablative HSCT. Patients might well react differently to vaccination after a reducedintensity conditioning transplantation and such studies should be performed. Therefore, our practice is to initiate influenza vaccination as early as 3-4 months after HSCT in epidemiological situations when high risk for influenza infection exists. However, if the vaccine is given earlier than 6 months after HSCT, a second dose could be contemplated, whereas the current data do not support a second dose in adults and older children vaccinated more than 6 months after HSCT. Additionally, to allow sufficient time for the patient to experience an immunologic response to influenza vaccine, chemoprophylaxis with neuraminidase inhibitors could be used for 2 weeks after vaccination in HSCT recipients during nosocomial or community influenza A outbreak.
To give antiviral chemoprophylaxis during a community outbreak is also important for children, as healthy children, who receive influenza vaccination for the first time might not generate protective antibodies until 2 weeks after receipt of the second dose of influenza vaccine. Therefore, during an influenza A outbreak, pediatric recipients o9 years of age receiving their first influenza vaccination 30 should receive two doses 4 weeks apart and might in addition benefit from influenza A chemoprophylaxis.
The data to support the necessity for yearly, life-long vaccination in disease-free long-term survivors after either an autologous HSCT or an allogeneic HSCT in patients without GVHD or ongoing immune suppression are mostly lacking. However, as the side effects from the vaccine are very limited, the reasoning behind the recommendation has been that the risk-benefit ratio favour vaccination.
It is also logical to attempt to reduce the risk for influenza transmission to patients not developing a protective immune response after vaccination. Therefore, influenza vaccination of family members and close or household contacts is strongly recommended during each influenza season to limit the risk for influenza exposure in HSCT candidates or recipients. It is also recommended that family members and close or household contacts of HSCT recipients should continue to be vaccinated annually as long as the HSCT recipient's immunocompromised state persists. Seasonal influenza vaccination is also strongly recommended for health-care workers dealing with HSCT recipients.
Future studies
As the existing data are limited, additional studies are needed for example evaluating the response rates to influenza vaccine in patients undergoing reduced-intensity HSCT, haplo-identical HSCT and transplants using cord blood grafts. In addition, the safety and efficacy of the live, cold-adapted intranasal vaccine for example in patients more than 2 years after HSCT without GVHD or ongoing immunosuppression would be useful, as the response rates with this vaccine are superior than for the conventional inactivated vaccine in healthy individuals.
